Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

on

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration134.

Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose13.

Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026132.

Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 202613.

Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data35.

Sources:

1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust

2. https://www.pharmaceutical-technology.com/analyst-comment/jpm26-pfizers-metsera-deal-supercharges-its-obesity-strategy/

3. https://www.fiercebiotech.com/biotech/pfizers-10b-monthly-glp-1-bet-generates-competitive-weight-loss-phase-2b

4. https://www.bioworld.com/articles/728543-pfizers-metsera-glp-1-hits-mark-for-once-monthly-dosing

5. https://www.biospace.com/business/pfizers-early-metsera-data-leaves-analysts-wanting-more